Hester Biosciences Ltd
HESTERBIOHester Biosciences Ltd
HESTERBIOPrice Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
103.05 | 6.58 | 0.26% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
51.22 | 6.55 | 0.48% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Hester Biosciences Limited is engaged in manufacturing of poultry vaccines and large animal vaccines, and trading of poultry health products and large animal health products. Its segments include Poultry Division and Large Animal Division.
Peers
Compare with peersBiocon Ltd
Panacea Biotec Ltd
Zenotech Laboratories Ltd
Transgene Biotek Ltd
Vivo Bio Tech Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Revenue Forecast
Earnings Per Share Forecast
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 101.77 | 123.53 | 138.49 | 185.28 | 189.64 | 219.01 | 249.17 | 285.65 | 319.80 | 313.77 | ||||||||||
Raw Materials | 22.53 | 29.11 | 35.39 | 41.92 | 44.15 | 46.63 | 75.41 | 82.74 | 87.14 | 242.02 | ||||||||||
Power & Fuel Cost | 5.81 | 5.59 | 6.37 | 7.83 | 8.13 | 7.57 | 10.28 | 12.74 | 15.30 | |||||||||||
Employee Cost | 15.44 | 18.32 | 23.24 | 28.93 | 40.65 | 38.92 | 45.33 | 56.02 | 64.13 | |||||||||||
Selling & Administrative Expenses | 13.55 | 15.93 | 17.92 | 24.99 | 37.78 | 35.47 | 40.18 | 54.77 | 56.48 | |||||||||||
Operating & Other expenses | 10.18 | 13.15 | 5.75 | 6.36 | -2.85 | 20.41 | 3.82 | 9.22 | 27.85 | |||||||||||
EBITDA | 34.26 | 41.43 | 49.82 | 75.25 | 61.78 | 70.01 | 74.15 | 70.16 | 68.90 | 71.75 | ||||||||||
Depreciation/Amortization | 5.75 | 7.00 | 9.66 | 11.76 | 13.07 | 13.31 | 16.58 | 20.70 | 17.17 | 15.90 | ||||||||||
PBIT | 28.51 | 34.43 | 40.16 | 63.49 | 48.71 | 56.70 | 57.57 | 49.46 | 51.73 | 55.85 | ||||||||||
Interest & Other Items | 3.72 | 3.50 | 4.04 | 6.63 | 7.37 | 6.60 | 4.06 | 9.32 | 19.78 | 22.22 | ||||||||||
PBT | 24.79 | 30.93 | 36.12 | 56.86 | 41.34 | 50.10 | 53.51 | 40.14 | 31.95 | 33.63 | ||||||||||
Taxes & Other Items | 5.62 | 7.38 | 10.51 | 15.29 | 12.16 | 15.68 | 14.17 | 13.53 | 13.07 | 14.29 | ||||||||||
Net Income | 19.17 | 23.55 | 25.61 | 41.57 | 29.18 | 34.42 | 39.34 | 26.61 | 18.88 | 19.34 | ||||||||||
EPS | 22.53 | 27.68 | 30.11 | 48.87 | 34.30 | 40.46 | 46.25 | 31.28 | 22.19 | 22.73 | ||||||||||
DPS | 4.10 | 5.30 | 10.00 | 11.00 | 6.60 | 10.00 | 10.00 | 8.00 | 6.00 | 8.00 | ||||||||||
Payout ratio | 0.18 | 0.19 | 0.33 | 0.23 | 0.19 | 0.25 | 0.22 | 0.26 | 0.27 | 0.35 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CareBiotechnology
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Hester Biosciences Ltd | 105.56 | 6.58 | 0.26% |
Biocon Ltd | 40.55 | 1.64 | 0.14% |
Panacea Biotec Ltd | -1,608.22 | 2.23 | — |
Zenotech Laboratories Ltd | 63.73 | 5.84 | — |
Price Comparison
Compare HESTERBIO with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Shareholding History
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Trend In Dividends
HESTERBIO has shown inconsistent dividend trend over the last 5 years
Dividend Yield
Current dividend yield is 0.26%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹2.56 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateAug 22, 2024
Dividend/Share
₹6.00
Ex DateEx Date
Aug 22, 2024
Cash Dividend
Ex DateEx DateSep 13, 2023
Dividend/Share
₹8.00
Ex DateEx Date
Sep 13, 2023
Cash Dividend
Ex DateEx DateAug 11, 2022
Dividend/Share
₹10.00
Ex DateEx Date
Aug 11, 2022
Cash Dividend
Ex DateEx DateAug 5, 2021
Dividend/Share
₹10.00
Ex DateEx Date
Aug 5, 2021
Cash Dividend
Ex DateEx DateAug 27, 2020
Dividend/Share
₹6.60
Ex DateEx Date
Aug 27, 2020
Net profit of Hester Biosciences rose 8.01% to Rs 6.34 crore in the quarter ended June 2024 as against Rs 5.87 crore during the previous quarter ended June 2023. Sales declined 6.35% to Rs 82.27 crore in the quarter ended June 2024 as against Rs 87.85 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales82.2787.85 -6 OPM %21.4516.35 - PBDT14.7314.31 3 PBT10.598.91 19 NP6.345.87 8 Powered by Capital Market - Live
Hester Biosciences announced that the Annual General Meeting (AGM) of the company will be held on 29 August 2024.Powered by Capital Market - Live
Hester Biosciences will hold a meeting of the Board of Directors of the Company on 2 August 2024.Powered by Capital Market - Live
Hester Biosciences Ltd leads gainers in ‘B’ group
Hester Biosciences to repurpose BSL-3 facility as Covid vaccine demand tapers off
Hester Biosciences to develop inactivated influenza vaccine for poultry
HesterBio gains on acquiring technology for H9N2 avian influenza virus vaccine from ICAR - NIHSAD
Hold Hester Biosciences; target of Rs 2070: ICICI Direct
Hester Biosciences Ltd leads losers in ‘A’ group
Hester Biosciences boosted by strong demand for goat pox vaccine
Lower than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 11.53%, vs industry avg of 19.21%
Decreasing Market Share
Over the last 5 years, market share decreased from 2.68% to 1.92%
Lower than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of -14.6%, vs industry avg of 1.42%